Work

Abstract CT092: A Phase 1a/1b, first-in-human study of an ADC targeting ADAM9 (DB-1317) in participants with selected advanced or metastatic solid tumors

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct092

Authors: Charlotte Lemech, Alexander Spira, David Sommerhalder, Siqing Fu, Feijiao Ge, Hua Mu, Yang Yang, Yang Qiu, Jiajia Chen, Rong Shi, Zhongyuan Zhu, Ruihua Xu

Institutions: The University of Texas MD Anderson Cancer Center, Duality Biotherapeutics, Inc. (China), Sun Yat-sen University Cancer Center

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154687956

Cites:

Cited by:

Related to: